Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of treatment weighting

Hiroshi Imaoka¹, Masafumi Ikeda², Satoshi Kobayashi³, Akihiro Ohba^{4

5}, Masayuki Ueno^{6

7}, Yuko Suzuki⁸, Hidetaka Tsumura⁹, Nana Kimura¹⁰, Shinya Kawaguchi¹¹, Yasuyuki Kawamoto¹², Kohei Nakachi¹³, Kunihiro Tsuji¹⁴, Noritoshi Kobayashi¹⁵, Reiko Ashida¹⁶, Naohiro Okano¹⁷, Kumiko Umemoto¹⁸, Gou Murohisa¹⁹, Ayumu Hosokawa²⁰, Akinori Asagi²¹, Hiroko Nebiki²², Rei Suzuki²³, Takeshi Terashima²⁴, Ryusuke Shibata²⁵, Kazuhito Kawata²⁶, Toshifumi Doi²⁷, Hiroshi Ohyama²⁸, Yohei Kitano²⁹, Kazuhiko Shioji³⁰, Hiroyuki Okuyama³¹, Atsushi Naganuma³², Yuji Negoro³³, Yasunari Sakamoto³⁴, Satoshi Shimizu⁸, Chigusa Morizane⁴, Makoto Ueno³, Junji Furuse³, Hiroaki Nagano³⁵; Japan Oncology Network in Hepatobiliary and Pancreas

Affiliations

¹ Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan. hiimaoka@east.ncc.go.jp.
² Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
³ Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
⁴ Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
⁵ Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
⁶ Department of Gastroenterology and Hepatology, Kurashiki Central Hospital, Kurashiki, Japan.
⁷ Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
⁸ Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan.
⁹ Department of Gastroenterological Oncology, Hyogo Cancer Center, Akashi, Japan.
¹⁰ Department of Surgery and Science, Faculty of Medicine, University of Toyama, Toyama, Japan.
¹¹ Department of Gastroenterology, Shizuoka General Hospital, Shizuoka, Japan.
¹² Division of Cancer Center, Hokkaido University Hospital, Sapporo, Japan.
¹³ Department of Medical Oncology, Tochigi Cancer Center, Utsunomiya, Japan.
¹⁴ Department of Gastroenterology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan.
¹⁵ Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan.
¹⁶ Second Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
¹⁷ Department of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, Japan.
¹⁸ Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan.
¹⁹ Department of Gastroenterology, Seirei Hamamatsu General Hospital, Hamamatsu, Japan.
²⁰ Department of Clinical Oncology, University of Miyazaki Hospital, Miyazaki, Japan.
²¹ Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
²² Department of Gastroenterology, Osaka City General Hospital, Osaka, Japan.
²³ Department of Gastroenterology, Fukushima Medical University, Fukushima, Japan.
²⁴ Department of Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan.
²⁵ Digestive and Lifestyle Diseases, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
²⁶ Hepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Hamamatsu, Japan.
²⁷ Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
²⁸ Department of Gastroenterology, Chiba University, Chiba, Japan.
²⁹ Division of Gastroenterology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan.
³⁰ Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan.
³¹ Department of Medical Oncology, Kagawa University Hospital, Miki, Japan.
³² Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Gunma, Japan.
³³ Department of Oncological Medicine, Kochi Health Sciences Center, Kochi, Japan.
³⁴ Department of Gastroenterology and Hepatology, International University of Health and Welfare Atami Hospital, Shizuoka, Japan.
³⁵ Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Japan.

PMID: 39878838
PMCID: PMC11880035
DOI: 10.1007/s00535-025-02215-1

Published Erratum

Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of treatment weighting

Hiroshi Imaoka et al. J Gastroenterol. 2025 Mar.

. 2025 Mar;60(3):368-369.

doi: 10.1007/s00535-025-02215-1.

Authors

Affiliations

¹ Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan. hiimaoka@east.ncc.go.jp.
² Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
³ Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
⁴ Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
⁵ Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
⁶ Department of Gastroenterology and Hepatology, Kurashiki Central Hospital, Kurashiki, Japan.
⁷ Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
⁸ Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan.
⁹ Department of Gastroenterological Oncology, Hyogo Cancer Center, Akashi, Japan.
¹⁰ Department of Surgery and Science, Faculty of Medicine, University of Toyama, Toyama, Japan.
¹¹ Department of Gastroenterology, Shizuoka General Hospital, Shizuoka, Japan.
¹² Division of Cancer Center, Hokkaido University Hospital, Sapporo, Japan.
¹³ Department of Medical Oncology, Tochigi Cancer Center, Utsunomiya, Japan.
¹⁴ Department of Gastroenterology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan.
¹⁵ Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan.
¹⁶ Second Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
¹⁷ Department of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, Japan.
¹⁸ Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan.
¹⁹ Department of Gastroenterology, Seirei Hamamatsu General Hospital, Hamamatsu, Japan.
²⁰ Department of Clinical Oncology, University of Miyazaki Hospital, Miyazaki, Japan.
²¹ Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
²² Department of Gastroenterology, Osaka City General Hospital, Osaka, Japan.
²³ Department of Gastroenterology, Fukushima Medical University, Fukushima, Japan.
²⁴ Department of Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan.
²⁵ Digestive and Lifestyle Diseases, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
²⁶ Hepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Hamamatsu, Japan.
²⁷ Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
²⁸ Department of Gastroenterology, Chiba University, Chiba, Japan.
²⁹ Division of Gastroenterology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan.
³⁰ Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan.
³¹ Department of Medical Oncology, Kagawa University Hospital, Miki, Japan.
³² Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Gunma, Japan.
³³ Department of Oncological Medicine, Kochi Health Sciences Center, Kochi, Japan.
³⁴ Department of Gastroenterology and Hepatology, International University of Health and Welfare Atami Hospital, Shizuoka, Japan.
³⁵ Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Japan.

PMID: 39878838
PMCID: PMC11880035
DOI: 10.1007/s00535-025-02215-1

No abstract available

PubMed Disclaimer

Erratum for

Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of treatment weighting.
Imaoka H, Ikeda M, Kobayashi S, Ohba A, Ueno M, Suzuki Y, Tsumura H, Kimura N, Kawaguchi S, Kawamoto Y, Nakachi K, Tsuji K, Kobayashi N, Ashida R, Okano N, Umemoto K, Murohisa G, Hosokawa A, Asagi A, Nebiki H, Suzuki R, Terashima T, Shibata R, Kawata K, Doi T, Ohyama H, Kitano Y, Shioji K, Okuyama H, Naganuma A, Negoro Y, Sakamoto Y, Shimizu S, Morizane C, Ueno M, Furuse J, Nagano H; Japan Oncology Network in Hepatobiliary and Pancreas. Imaoka H, et al. J Gastroenterol. 2025 Mar;60(3):356-367. doi: 10.1007/s00535-024-02186-9. Epub 2024 Nov 30. J Gastroenterol. 2025. PMID: 39614927 Free PMC article.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- PubMed Central
- Springer

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of treatment weighting

Affiliations

Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of treatment weighting

Authors

Affiliations

Erratum for

Publication types

LinkOut - more resources

Full Text Sources